Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PRLD |
---|---|---|
09:32 ET | 986 | 2.24 |
09:38 ET | 2300 | 2.2 |
09:39 ET | 250 | 2.22 |
09:41 ET | 1143 | 2.195 |
09:48 ET | 400 | 2.19 |
09:50 ET | 100 | 2.19 |
09:52 ET | 547 | 2.2 |
09:56 ET | 1685 | 2.2 |
09:57 ET | 200 | 2.2 |
09:59 ET | 300 | 2.19 |
10:01 ET | 200 | 2.19 |
10:03 ET | 100 | 2.2 |
10:08 ET | 200 | 2.2 |
10:15 ET | 100 | 2.19 |
10:21 ET | 400 | 2.185 |
10:24 ET | 3101 | 2.19 |
10:28 ET | 1081 | 2.19 |
10:30 ET | 2700 | 2.17 |
10:33 ET | 100 | 2.16 |
10:37 ET | 1000 | 2.16 |
10:42 ET | 100 | 2.16 |
10:44 ET | 100 | 2.17 |
10:46 ET | 1724 | 2.19 |
10:50 ET | 850 | 2.19 |
10:51 ET | 997 | 2.195 |
10:55 ET | 100 | 2.19 |
10:57 ET | 400 | 2.19 |
11:00 ET | 200 | 2.195 |
11:02 ET | 857 | 2.19 |
11:06 ET | 3000 | 2.19 |
11:08 ET | 229 | 2.17 |
11:09 ET | 338 | 2.18 |
11:18 ET | 100 | 2.19 |
11:22 ET | 750 | 2.195 |
11:27 ET | 100 | 2.2 |
11:29 ET | 100 | 2.195 |
11:33 ET | 1330 | 2.2 |
11:40 ET | 700 | 2.18 |
11:44 ET | 200 | 2.19 |
11:45 ET | 200 | 2.1922 |
11:56 ET | 300 | 2.195 |
11:58 ET | 100 | 2.19 |
12:03 ET | 100 | 2.195 |
12:05 ET | 800 | 2.18 |
12:07 ET | 2574 | 2.185 |
12:09 ET | 10026 | 2.195 |
12:14 ET | 100 | 2.18 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Prelude Therapeutics Inc | 121.6M | -1.2x | --- |
Fractyl Health Inc | 121.3M | -1.9x | --- |
Skye Bioscience Inc | 120.1M | -0.9x | --- |
Invivyd Inc | 124.2M | -0.6x | --- |
Actuate Therapeutics Inc | 118.6M | -4.5x | --- |
Adicet Bio Inc | 115.4M | -0.6x | --- |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $121.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 55.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.51 |
EPS | $-1.80 |
Book Value | $5.64 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.